DelveInsight’s “Athlete’s Foot Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Athlete’s Foot pipeline landscapes. It comprises Athlete’s Foot pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Athlete’s Foot therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Athlete’s Foot pipeline products.
Some of the key takeaways of the Athlete’s Foot Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Blueberry Therapeutics Ltd, DermBiont, etc., are developing therapies to treat athletes’ feet.
-
Emerging therapies such as BB2603, DBI-001, are expected to have a significant impact on the Athlete’s Foot market in the coming years.
-
Douglas Pharmaceuticals America in collaboration with ACM Global Laboratories and Novum Pharmaceutical Research Services initiated a phase III randomized, double-blind,vehicle-controlled, parallel-design,multiple-site study to evaluate the therapeutic equivalence of ketoconazole cream 2% to Ketoconazole Cream 2% in the treatment of Tinea Pedis.
Get an overview of pipeline landscape @ Athlete’s Foot Clinical Trials Analysis
An athlete’s foot is a fungal infection that affects the upper layer of the skin of the foot, especially when it is warm, moist, and irritated. It is also known as tinea Pedi and ringworm of the foot. The fungus that causes an athlete’s foot is called Trichophyton and is commonly found on floors and in clothing.
Athlete’s Foot Emerging Drugs
-
BB2603 by Blueberry Therapeutics Ltd
-
DBI-001 by DermBiont
-
And others.
Scope of Athlete’s Foot Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Blueberry Therapeutics Ltd, DermBiont, and others.
-
Pipeline Therapies: BB2603, DBI-001, and others.
Table of Contents
|
1 |
Athlete’s Foot Report Introduction |
|
2 |
Athlete’s Foot Executive Summary |
|
3 |
Athlete’s Foot Overview |
|
4 |
Athlete’s Foot- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Athlete’s Foot Pipeline Therapeutics |
|
6 |
Athlete’s Foot Late Stage Products (Phase II/III) |
|
7 |
Athlete’s Foot Mid Stage Products (Phase II) |
|
8 |
Athlete’s Foot Early Stage Products (Phase I) |
|
9 |
Athlete’s Foot Preclinical Stage Products |
|
10 |
Athlete’s Foot Therapeutics Assessment |
|
11 |
Athlete’s Foot Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Athlete’s Foot Key Companies |
|
14 |
Athlete’s Foot Key Products |
|
15 |
Athlete’s Foot Unmet Needs |
|
16 |
Athlete’s Foot Market Drivers and Barriers |
|
17 |
Athlete’s Foot Future Perspectives and Conclusion |
|
18 |
Athlete’s Foot Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s ‘Athlete’s Foot – Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the Athlete’s Foot, historical and forecasted epidemiology as well as the Athlete’s Foot market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s ‘Athlete’s Foot- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Athlete’s Foot epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/